Suzhou Zelgen Biopharmaceuticals Co., Ltd. (SHA:688266)

Market Cap	29.21B
Revenue (ttm)	742.28M
Net Income (ttm)	-133.34M
Shares Out	264.71M
EPS (ttm)	-0.50
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,404,945
Average Volume	2,338,891
Open	112.43
Previous Close	111.32
Day's Range	107.55 - 112.43
52-Week Range	58.00 - 134.17
Beta	0.20
RSI	56.67
Earnings Date	Oct 31, 2025

About SHA:688266

Suzhou Zelgen Biopharmaceuticals Co., Ltd. researches and develops, manufactures, and sells medicines in the People's Republic of China. It offers donafenib tablets; recombinant human thrombin for topincal use; jacktinib tablets; and recombinant human thyroid-stimulating hormone for injection; obeticholic acid magnesium tablets; ZG19018 tablets; ZG005 powder for injection; and alkotinib capsules for the treatment of liver cancer, non-small cell lung cancer, small cell lung cancer, colorectal cancer, thyroid cancer, and neuroendocrine cancer, as...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2009
• Employees: 910
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688266

Financial Performance

In 2024, SHA:688266's revenue was 532.95 million, an increase of 37.91% compared to the previous year's 386.44 million. Losses were -137.83 million, -50.52% less than in 2023.